ALS/MND Natural History Study Data Repository

Description

This is a data repository for multi-site multi-protocol clinic-based Natural History Study of ALS and Other Motor Neuron Disorders (MND). All people living with ALS or other MNDs who attend clinics at the Study hospitals (sites) are offered to participate in the Study. The Sites collect so-called Baseline information including demographics, disease history and diagnosis, family history, etc. At each visit, the Sites also collect multiple disease-specific outcome measures and events. The information is captured in NeuroBANK, a patient-centric clinical research platform. The Sites have an option to choose to collect data into 20+ additional forms capturing biomarkers and outcome measures. Captured data after its curation are anonymized (all personal identifiers and dates are being removed), and the anonymized dataset is shared with medical researchers via a non-exclusive revocable license. Funding Source - Biogen, Inc.; Mitsubishi Tanabe Pharma America; FDA OOPD.

Conditions

ALS, PLS, MND (Motor Neurone DIsease), Kennedy Disease, PMA - Progressive Muscular Atrophy, PBP - Progressive Bulbar Palsy

Study Overview

Study Details

Study overview

This is a data repository for multi-site multi-protocol clinic-based Natural History Study of ALS and Other Motor Neuron Disorders (MND). All people living with ALS or other MNDs who attend clinics at the Study hospitals (sites) are offered to participate in the Study. The Sites collect so-called Baseline information including demographics, disease history and diagnosis, family history, etc. At each visit, the Sites also collect multiple disease-specific outcome measures and events. The information is captured in NeuroBANK, a patient-centric clinical research platform. The Sites have an option to choose to collect data into 20+ additional forms capturing biomarkers and outcome measures. Captured data after its curation are anonymized (all personal identifiers and dates are being removed), and the anonymized dataset is shared with medical researchers via a non-exclusive revocable license. Funding Source - Biogen, Inc.; Mitsubishi Tanabe Pharma America; FDA OOPD.

ALS/MND Natural History Study Data Repository

ALS/MND Natural History Study Data Repository

Condition
ALS
Intervention / Treatment

-

Contacts and Locations

Gainesville

University of Florida, Gainesville, Florida, United States, 32610

Chicago

Northwestern University, Chicago, Illinois, United States, 60611

Burlington

Lahey Clinic, Burlington, Massachusetts, United States, 01805

Detroit

Henry Ford Health System, Detroit, Michigan, United States, 48202

Minneapolis

University of Minnesota, Minneapolis, Minnesota, United States, 55455

Saint Louis

Saint Louis University, Saint Louis, Missouri, United States, 63104

Portland

Providence ALS Clinic, Portland, Oregon, United States, 97213

Philadelphia

Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, United States, 19140

Pittsburgh

University of Pittsburgh, Pittsburgh, Pennsylvania, United States, 15360

Richmond

Virginia Commonwealth University, Richmond, Virginia, United States, 22908

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * A clinical diagnosis of El Escorial of suspected, possible, probable, or definite ALS or
  • * Other motor neuron disorders, including but not limited to Spinal-Bulbar Muscular Atrophy (SBMA, Kennedy's disease), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), and Progressive Bulbar Palsy (PBP)
  • * Disease does not meet criteria for any motor neuron disorder

Ages Eligible for Study

18 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts General Hospital,

Alexander Sherman, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

2030-12-31